Verona Pharma Company Overview
About Verona Pharma
Verona Pharma (NASDAQ:VRNA) focuses on developing and commercializing innovative respiratory drugs for patients suffering from diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Their flagship project revolves around Ensifentrine, a first-in-class product candidate designed to treat a broad spectrum of respiratory ailments, demonstrating a unique dual mechanism that combines bronchodilator and anti-inflammatory properties. With a commitment to improving the quality of life for people with respiratory diseases, Verona Pharma is intently focused on advancing their clinical trials, aiming to bring new, effective treatments to the market. Their objectives include the successful completion of these trials, securing regulatory approval, and ultimately, the global commercialization of their therapies.
Snapshot
Operations
Produtos e/ou serviços de Verona Pharma
- Ensifentrine, a first-in-class product targeting the treatment of respiratory diseases including COPD and cystic fibrosis, by combining bronchodilator and anti-inflammatory properties in one compound.
- Clinical trials for the nebulized form of ensifentrine, aimed at assessing its efficacy and safety in COPD patients over long-term use.
- Development of a dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) versions of ensifentrine for easier administration and improved patient compliance.
- Research partnerships focused on exploring ensifentrine’s potential benefits in treating other respiratory diseases beyond COPD, such as asthma.
- Outreach and engagement with regulatory agencies for the approval process of ensifentrine in key markets, including the United States and Europe.
- Patient support programs designed to improve access and adherence to treatments among those diagnosed with COPD and other respiratory conditions.
equipe executiva do Verona Pharma
- Dr. David Scott Zaccardelli Pharm.D.President, CEO & Executive Director
- Mr. Mark W. Hahn CPAChief Financial Officer
- Mr. Andrew FisherGeneral Counsel
- Dr. Kathleen A. Rickard M.D.Chief Medical Officer
- Ms. Victoria StewartSenior Director of Investor Relations & Communications
- Mr. Matthew CasbonVP of Sales, Marketing & Training
- Ms. Ostra JewellSenior Vice President of Human Resources
- Dr. Tara Rheault M.P.H., Ph.D.Chief Development Officer
- Mr. Christopher MartinChief Commercial Officer
- Ms. Caroline DiazChief Regulatory Officer